After a few quarters of "are they or aren't they?" uncertainty about Accuray's (ARAY)
turnaround, I think this quarter was a significant step forward for the
company. Product revenue and orders have both recovered to pre-merger
levels and attitudes regarding the systems appear to have turned solidly
to the positive. Valuation is becoming a trickier issue now and
although the shares are not all that cheap anymore from a cash flow
standpoint, the shares could still do well by the looser standards of
med-tech investors.
Please read more here:
Accuray Now Solidly On The Right Path
No comments:
Post a Comment